Transferrin is one of the key proteins of iron metabolism in mammalians. It is responsible for the transfer of the essential iron(Ill) ions through the biological fluids from absorption to storage and utilization sites. Moreover, transferdn is involved in the metabolism of other metal ions that are either trace or toxic elements. In recent years the crystal structure of transferrin has been solved at high resolution. This has allowed an extensive reinterpretation of the many spectroscopic studies carried out on this protein in the last decade as well as the elucidation of some interesting structure-function relationships. We review here recent progresses in transferrin biochemistry, particular focus being given to those aspects that are relevant from a medical point of view.
1, Inorganic Biochemistry of Transferrins.
Transferrins constitute an homologous family of monomeric glycoproteins whose primary members are serum transferrin, lactoferdn and ovotransferdn [1] . Transferrins [2, 3] . Such arrangement allows a large molecular flexibility and turns out to be a critical factor for the function of transferrins ( Figure 1 ). The structure of the two virtually identical metal binding sites has been determined in detail. Iron is octahedrally coordinated by four protein donors (namely two Tyr phenolates, one His imidazole and one Asp carboxylate) Domain Transfetwn: From Inorganic Biochemistry to Medicine and by the bidentate carbonate anion. The carbonate anion fits into a pocket between the iron atom and two positively charged protein groups, an arginine side chain and a helix N-terminus. The structure of the metal binding sites is shown in Figure 2 .
Inspection of the metal binding site structure provides an insight into the probable mechanism of metal uptake. It has been hypothesized that the protein first binds the synergistic anion and the metal at domain I, then domain II closure occurs and the coordination shell of the iron(Ill) ions is completed through the carboxylate group of Asp [4] . The Plutonium: Because of the extensive manipulations involving plutonium in the nuclear weapons industry accidents involving this element occur with a certain frequency. The biological transport and storage of plutonium(IV) is similar to that of iron(Ill) and this characteristic provides the rationale for the most recent developments in decontamination strategies. It was shown that EDTA type compounds, of which DTPA is the most effective member, are capable of significantly enhancing the excretion of Pu-239 [13, 21] . The many similarities between Pu(IV) and Fe(lll) stimulated the search for chelating agents with donor groups similar to those of the naturally occurring iron binding compounds, the so called sidemphores, synthetized by various microrganisms. Indeed, desferrioxamine can mobilize Pu-239 from most organs with the exception of the kidney [13] . Among the other tested ligands LICAMS are the most effective ones [13, 22] . It has been reported that the removal of an injected dose of Pu-239 by these chelating agents was approximately the same as found for DTPA, but the new ligands have the advantage of an even lower reactivity at physiological pH with essential divalent metal ions and the ability to remove some of the Pu(IV) already deposited in the bone. This development is a striking demonstration of the design of a new selective chelating agent for a toxic metal on the basis of an effective understanding of its coordination properties. Aluminum: Although aluminum has no known biological function, a toxic amount of aluminum can cause dialysis encephalopathy in humans and is associated with other degenerative disorders such as senile dementia of the Alzheimer type. In vitro the binding of aluminum(Ill) to transferrin has been probed by a number of spectroscopic techniques [23, 24] . Plasma speciation studies point to transferrin as the major carrier protein of aluminum(Ill). Recent evidence suggests that Tf from people affected with Alzheimer disease may be deficient in its ability to complex and remove aluminum contributing to the deposition of high levels of this metal in the brain [25] . In other words the aluminum toxicity would greatly increase when the binding capacity of transferrin is saturated; low molecular weight aluminum(Ill) complexes would form that are capable of crossing the blood-brain barrier. These findings led to the belief that the use of aluminum chelators might well provide a therapeutic rationale for the treatment of aluminum toxicity. Both apotransferrin and desferrioxamine B are being tested for the treatment of aluminum toxicity. 
Concluding Remarks
The knowledge of transferrin has increased in recent years thanks to the determination of its X-ray structure and to a host of spectroscopic and kinetic studies. Studies on site specific mutants obtained through recombinant techniques have now the potential to elucidate the role of individual residues in the thermodynamics and kinetics of the metal binding/release reactions. This will help designing new ligands capable of scavenging metals from transferrin with high selectivity and efficiency. Moreover, we have described the expanding role of transferdn in medicine. Transferrin indeed is involved in several processes of large biomedical concern such as treatment of iron overload, detoxification of heavy metal poisoning, delivery of radiopharmaceuticals, drag targeting, treatment of the Alzheimer disease, control of cell proliferation, etc. We feel that a deeper knowledge of the bioinorganic chemistry of transferdn will contribute significantly to these medical developments.
